Beam Therapeutics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M | $24.0K | $18.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $409.6M | $367.6M | $437.4M | $311.6M | $387.1M | $103.2M | $54.6M |
| SG&A Expense | — | $113.8M | $111.5M | $116.8M | $87.8M | $57.2M | $29.6M | $20.6M |
| Operating Income | — | $-383.7M | $-415.6M | $-176.5M | $-338.5M | $-392.5M | $-132.8M | $-75.2M |
| Operating Margin | — | -274.6% | -654.3% | -46.7% | -555.6% | -757.0% | -553,166.7% | -417,522.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-80.0M | $-376.7M | $-131.2M | $-260.2M | $-370.6M | $-194.6M | — |
| Income Tax Expense | — | $0 | $39.0K | $1.4M | $3.4M | $0 | $0 | $0 |
| Net Income | — | $-80.0M | $-376.7M | $-132.5M | $-289.1M | $-370.6M | $-194.6M | $-78.3M |
| Net Margin | — | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | -810,800.0% | -435,144.4% |
| EPS (Basic) | — | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-4.19 | $-2.01 |
| EPS (Diluted) | — | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-4.19 | $-2.01 |
| Shares Outstanding (Basic) | 101.9M | 98.9M | 82.3M | 77.2M | 70.0M | 64.2M | 46.7M | 45.4M |
| Shares Outstanding (Diluted) | 101.9M | 98.9M | 82.3M | 77.2M | 70.0M | 64.2M | 46.7M | 45.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |